Both therapeutic protocols resulted in clinical improvement in all animals; however, the combined use of prostaglandin modified the profile of oxidative markers, antioxidant enzymes, and C-reactive protein, thereby preventing the assessment of treatment efficacy in reversing the inflammatory and redox metabolism caused by pyometra. The gene discussed is CRP; the disease is pyometritis.